Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression

Journal of Viral Hepatitis

Volumn 15, Issue 2, 2008, Pages 108-114

  Leemans, W F ^a   Janssen, H L A ^a   Niesters, H G M ^a   De Man, R A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Adefovir; Failure; Lamivudine; Relapse; Resistance; Tenofovir; Treatment

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; LAMIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SUBSTITUTION; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRESCRIPTION; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS INHIBITION; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION;

ADENINE; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES; VIRAL LOAD; VIRUS REPLICATION;

EID: 37649011301     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00906.x     Document Type: Article

References (32)

1. Marcellin P., Lau GK, Bonino F et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004 351 (12 1206 1217.
2. Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005 365 (9454 123 129.
3. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998 339 (2 61 68.
4. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999 341 (17 1256 1263.
5. Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003 348 (9 808 816.
6. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003 348 (9 800 807.
7. Chang TT, Lai CL, Chien RN et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004 19 (11 1276 1282.
8. Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004 9 (3 353 363.
9. van Bommel F, Wunsche T, Mauss S et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004 40 (6 1421 1425.
10. de Vries-Sluijs TE, van der Eijk AA, Hansen BE, Osterhaus AD, de Man RA, van der Ende ME. Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine-/-tenofovir therapy in HIV-HBV co-infected patients. J Clin Virol 2006 36 (1 60 63.
11. Delaney WEt, Ray AS, Yang H et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006 50 (7 2471 2477.
12. Ray AS, Vela JE, Olson L, Fridland A. Effective metabolism and long intracellular half life of the anti-hepatitis B agent adefovir in hepatic cells. Biochem Pharmacol 2004 68 (9 1825 1831.
13. Delmas J, Schorr O, Jamard C et al. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob Agents Chemother 2002 46 (2 425 433.
14. Van Bommel F, Berg T. Reactivation of viral replication after replacement of tenofovir by adefovir. Hepatology 2005 42 (1 239 240.
15. Schildgen O, Hartmann H, Gerlich WH. Replacement of tenofovir with adefovir may result in reactivation of hepatitis B virus replication. Scand J Gastroenterol 2006 41 (2 245 246.
16. Heermann KH, Gerlich WH, Chudy M, Schaefer S, Thomssen R. Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations. Eurohep Pathobiology Group. J Clin Microbiol 1999 37 (1 68 73.
17. Pas SD, Fries E, De Man RA, Osterhaus AD, Niesters HG. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol 2000 38 (8 2897 2901.
18. Stuyver LJ, Locarnini SA, Lok A et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001 33 (3 751 757.
19. Schildgen O, Sirma H, Funk A et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006 354 (17 1807 1812.
20. Nunez M, Perez-Olmeda M, Diaz B, Rios P, Gonzalez-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002 16 (17 2352 2354.
21. Ristig MB, Crippin J, Aberg JA et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus-/-hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002 186 (12 1844 1847.
22. van Bommel F, Wunsche T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002 36 (2 507 508.
23. van der Eijk AA, Hansen BE, Niesters HG et al. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants. J Viral Hepat 2005 12 (4 364 372.
24. Sheldon J, Camino N, Claussen G. Genotypic changes in HBV-DNA of HBV-/-HIV co-infected patients after long-term exposure to tenofovir. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Oct 30-Nov 2, 2004. Washington DC, USA, 2004.
25. Chang TT, Lai CL. Hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006 355 (3 322 323 (author reply 3).
26. Westland C, Delaney Wt, Yang H et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology 2003 125 (1 107 116.
27. Yurdaydin C, Senturk H, Boron-Kaczmarska A et al. Entecavir (ETV) demonstrates consistent responses throughout baseline disease and demograpic subgroups for the treatement of lamivudine-refractory HBeAg(+) patients with chronic hepatitis B. J Hepatol 2006 44 (Suppl. 2 S190 S191.
28. Orito E, Fujiwara K, Tanaka Y et al. A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. Hepatol Res 2006 35 (2 127 134.
29. Akuta N, Suzuki F, Kobayashi M et al. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 2003 38 (3 315 321.
30. Zollner B, Petersen J, Schroter M, Laufs R, Schoder V, Feucht HH. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 2001 357 (9260 934 935.
31. Fung SK, Chae HB, Fontana RJ et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006 44 (2 283 290.
32. Ying C, De Clercq E, Nicholson W, Furman P, Neyts J. Inhibition of the replication of the DNA polymerase M550 V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 2000 7 (2 161 165.